NO152129C - Analogifremgangsmaate for fremstilling av terapeutisk aktive omega-cyan-1, omega-difenyl-azaalkanderivater - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive omega-cyan-1, omega-difenyl-azaalkanderivater

Info

Publication number
NO152129C
NO152129C NO821085A NO821085A NO152129C NO 152129 C NO152129 C NO 152129C NO 821085 A NO821085 A NO 821085A NO 821085 A NO821085 A NO 821085A NO 152129 C NO152129 C NO 152129C
Authority
NO
Norway
Prior art keywords
omega
azaalkander
difenyl
cyan
derivatives
Prior art date
Application number
NO821085A
Other languages
English (en)
Norwegian (no)
Other versions
NO152129B (no
NO821085L (no
Inventor
Oskar Ehrmann
Manfred Raschack
Josef Gries
Rolf Kretzschmar
Hans Dieter Lehmann
Ludwig Friedrich
Dirk Wuppermann
Frank Zimmermann
Werner Seitz
Hans Joerg Treiber
Ferdinand Dengel
Wolfram Frank
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO821085L publication Critical patent/NO821085L/no
Publication of NO152129B publication Critical patent/NO152129B/no
Publication of NO152129C publication Critical patent/NO152129C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
NO821085A 1981-04-10 1982-03-31 Analogifremgangsmaate for fremstilling av terapeutisk aktive omega-cyan-1, omega-difenyl-azaalkanderivater NO152129C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3114497 1981-04-10
DE19813144150 DE3144150A1 (de) 1981-04-10 1981-11-06 (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel

Publications (3)

Publication Number Publication Date
NO821085L NO821085L (no) 1982-10-11
NO152129B NO152129B (no) 1985-04-29
NO152129C true NO152129C (no) 1985-08-07

Family

ID=25792602

Family Applications (1)

Application Number Title Priority Date Filing Date
NO821085A NO152129C (no) 1981-04-10 1982-03-31 Analogifremgangsmaate for fremstilling av terapeutisk aktive omega-cyan-1, omega-difenyl-azaalkanderivater

Country Status (19)

Country Link
US (1) US4438131A (da)
EP (1) EP0064158B1 (da)
AU (1) AU546383B2 (da)
CA (1) CA1184186A (da)
CS (4) CS238635B2 (da)
DD (1) DD201778A5 (da)
DE (2) DE3144150A1 (da)
DK (1) DK156513C (da)
ES (4) ES511260A0 (da)
FI (1) FI76550C (da)
GB (1) GB2100252B (da)
GR (1) GR75531B (da)
HU (1) HU186058B (da)
IE (1) IE54044B1 (da)
MX (1) MX9203501A (da)
NO (1) NO152129C (da)
PH (1) PH19739A (da)
SG (1) SG78584G (da)
SU (1) SU1308195A3 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3344755A1 (de) * 1983-12-10 1985-06-20 Basf Ag, 6700 Ludwigshafen 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten
DE3433383A1 (de) * 1984-09-12 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phenyl-acetonitril-derivate
US4612329A (en) * 1984-10-17 1986-09-16 Hokuriku Pharmaceutical Co., Ltd. Pharmaceutical alpha-aminoalkyl-alpha-alkylphenylacetonitriles
US4760089A (en) * 1985-09-09 1988-07-26 Smithkline Beckman Corporation Irreversible dopamine-β-hydroxylase inhibitors
FR2588258B1 (fr) * 1985-10-04 1989-12-15 Adir Nouveaux derives d'amino-5 valeronitrile, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
DE3535950A1 (de) * 1985-10-09 1987-04-09 Basf Ag Kombinationspraeparat
DE3535949A1 (de) * 1985-10-09 1987-04-09 Basf Ag Kombinationspraeparat
US4593042A (en) * 1985-10-18 1986-06-03 G. D. Searle & Co. Bicyclo-substituted phenylacetonitrile derivatives
GR862558B (en) * 1985-10-18 1987-02-12 Searle & Co Bicyclo-substituted phenylacetonitrile derivatives
DE3542994A1 (de) * 1985-12-05 1987-06-11 Basf Ag Basisch substituierte phenylacetaldehyde, ihre herstellung und diese enthaltende arzneimittel
DE3603032A1 (de) * 1986-01-31 1987-08-06 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
CS258534B1 (en) * 1986-07-18 1988-08-16 Ludvik Blaha Derivatives of valeronitrile and method of their preparation
DE3634389A1 (de) * 1986-10-09 1988-04-21 Knoll Ag Verwendung von anipamil
DE3642331A1 (de) * 1986-12-11 1988-06-23 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
ATE46439T1 (de) * 1986-12-13 1989-10-15 Basf Ag Kombinationspraeparat.
US5486539A (en) * 1989-12-21 1996-01-23 G. D. Searle & Co. Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5247119A (en) * 1990-12-12 1993-09-21 G. D. Searle & Co. Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
CS164891A3 (en) * 1991-05-31 1992-12-16 Vyzk Ustav Farm Biochem Sp N-arylalkyl derivatives of 2-aminomethyl-1,4-benzodioxan, and process forpreparing thereof
DE4124252A1 (de) * 1991-07-22 1993-01-28 Knoll Ag Verfahren zur herstellung einer sterilfiltrierbaren wirkstoffloesung
DE4234000A1 (de) * 1992-10-09 1994-04-14 Knoll Ag Verfahren zur Racemattrennung von Anipamil
CA2693627C (en) * 2007-06-20 2016-01-12 Milestone Pharmaceuticals Inc. Short acting phenylalkylamine calcium channel blockers and uses thereof
US9504747B2 (en) 2013-03-08 2016-11-29 Novartis Ag Lipids and lipid compositions for the delivery of active agents
JP6352950B2 (ja) * 2013-03-08 2018-07-04 ノバルティス アーゲー 活性薬物の送達のための脂質と脂質組成物
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA916719A (en) 1972-12-12 Dengel Ferdinand Basically substituted phenylacetonitriles and method for their preparation
DE1154810B (de) 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE1643429A1 (de) * 1967-09-20 1971-01-28 Knoll Ag Basisch substituierte Phenylacetonitrile und Verfahren zu deren Herstellung
GB1202500A (en) 1967-12-08 1970-08-19 Knoll Ag Substituted phenylacetonitriles
GB1202750A (en) 1967-12-11 1970-08-19 Knoll Ag Substituted phenylacetonitriles
DE2059985C3 (de) 1970-12-05 1979-10-04 Knoll Ag, 6700 Ludwigshafen Rechtsdrehende, basisch substituierte Phenylacetonitrile, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2059923C3 (de) 1970-12-05 1979-01-25 Knoll Ag, 6700 Ludwigshafen l-a-Isopropyl-o-[(N-methyl-N-homoveratryl)v-aminopropyl] -3,4-dimethoxyphenylacetonitril, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel
DE2946545A1 (de) * 1979-11-17 1981-05-27 Basf Ag, 6700 Ludwigshafen Verfahren zur gewinnung der enantiomeren formen von 4-cyan-1-(n-methyl-n-(2'-((3'',4'',-dimethoxyphenyl))-aethyl)-amino)-5-methyl-4-(3',4',5'-trimethoxyphenyl)-hexan und dessen salzen

Also Published As

Publication number Publication date
ES8402261A1 (es) 1984-01-16
CS238635B2 (en) 1985-12-16
ES8307210A1 (es) 1983-07-01
ES8402560A1 (es) 1984-02-01
ES8402262A1 (es) 1984-01-16
FI821252L (fi) 1982-10-11
FI821252A0 (fi) 1982-04-07
MX9203501A (es) 1992-09-01
ES521543A0 (es) 1984-02-01
FI76550B (fi) 1988-07-29
DK156513C (da) 1990-02-05
GB2100252B (en) 1984-06-27
DD201778A5 (de) 1983-08-10
GR75531B (da) 1984-07-26
EP0064158A1 (de) 1982-11-10
FI76550C (fi) 1988-11-10
CS238634B2 (en) 1985-12-16
AU546383B2 (en) 1985-08-29
HU186058B (en) 1985-05-28
DE3144150A1 (de) 1982-12-09
DK156513B (da) 1989-09-04
ES521545A0 (es) 1984-01-16
NO152129B (no) 1985-04-29
GB2100252A (en) 1982-12-22
US4438131A (en) 1984-03-20
SU1308195A3 (ru) 1987-04-30
SG78584G (en) 1985-04-26
DK159882A (da) 1982-10-11
IE54044B1 (en) 1989-05-24
CA1184186A (en) 1985-03-19
EP0064158B1 (de) 1985-03-13
PH19739A (en) 1986-06-23
CS238636B2 (en) 1985-12-16
DE3262516D1 (en) 1985-04-18
ES521544A0 (es) 1984-01-16
IE820856L (en) 1982-10-10
ES511260A0 (es) 1983-07-01
CS238621B2 (en) 1985-12-16
NO821085L (no) 1982-10-11
AU8249082A (en) 1983-04-21

Similar Documents

Publication Publication Date Title
NO162022C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive cefemderivater.
NO158099C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater.
NO156864C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive piperinderivater.
NO163451C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminomethyloxooxazolidinylbenzenderivater.
NO159446C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyril-derivater.
NO162764C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolinderivater.
NO163406C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinolinonderivater.
NO149102C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-4-fenyl-1,2,3,4-tetrahydro-1-naftalenamin-derivater
NO862477D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-arylimidazol-derivater.
NO165239C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-benzyl-aminoalkyl-pyrrolidinon-derivater.
NO152129C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive omega-cyan-1, omega-difenyl-azaalkanderivater
NO165192C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive glyserolderivater.
NO156787C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO814136L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 8-arylalkyl-3-fenyl-3-notropanol-derivater
NO159654C (no) Analogifremgangsm te for fremstilling av terapeutisk aktive 2-guanidin-4-heteroaryltiazolderivater.
NO161562C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ergolinderivater.
NO161676C (no) Analogifremgangsm te til fremstilling av terapeutisk aktive mitosanderivater.
NO158941C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-piperidino-kinazolinderivater.
NO161559C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive triazolderivater.
NO164897C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oxazolidinonderivater.
NO160079C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-derivater.
NO158739C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-piperazinopyrimidinderivater.
NO160511C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenyl-cyklo-butanderivater.
NO820112L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater
NO168478C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive vinylthioacetamido-oxacefalosporinderivater.